WO2006063355A3 - Cell free biosynthesis of high-quality nucleic acid and uses thereof - Google Patents

Cell free biosynthesis of high-quality nucleic acid and uses thereof Download PDF

Info

Publication number
WO2006063355A3
WO2006063355A3 PCT/US2005/045028 US2005045028W WO2006063355A3 WO 2006063355 A3 WO2006063355 A3 WO 2006063355A3 US 2005045028 W US2005045028 W US 2005045028W WO 2006063355 A3 WO2006063355 A3 WO 2006063355A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
applications
nucleic acid
cell free
nucleic acids
Prior art date
Application number
PCT/US2005/045028
Other languages
French (fr)
Other versions
WO2006063355A2 (en
Inventor
Yin Chen
Frederic Kendirgi
Frank Vazquez
Malcolm Skolnick
Original Assignee
Cytogenix Inc
Yin Chen
Frederic Kendirgi
Frank Vazquez
Malcolm Skolnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc, Yin Chen, Frederic Kendirgi, Frank Vazquez, Malcolm Skolnick filed Critical Cytogenix Inc
Priority to CA002590933A priority Critical patent/CA2590933A1/en
Priority to EP05853854A priority patent/EP1819828A2/en
Priority to US11/792,800 priority patent/US20080305142A1/en
Priority to AU2005314431A priority patent/AU2005314431B2/en
Priority to BRPI0515777-3A priority patent/BRPI0515777A/en
Priority to JP2007545717A priority patent/JP2008522628A/en
Priority to PCT/US2006/023439 priority patent/WO2007018744A2/en
Publication of WO2006063355A2 publication Critical patent/WO2006063355A2/en
Publication of WO2006063355A3 publication Critical patent/WO2006063355A3/en
Priority to IL183778A priority patent/IL183778A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/101—DNA polymerase

Abstract

The invention provides an improved cell free amplification method capable of producing large quantities of therapeutic-quality nucleic acids and methods of using the synthesized nucleic acid in research, therapeutic and other applications- The methods combine several different state-of-the-art procedures and coordinate their applications to affordably synthesize nucleic acids for therapeutic purposes. It combines in vitro rolling circle amplification, high fidelity polymerases, high affinity primers, and streamlined template specifically designed for particular applications. For expression purposes, the templates contain an expression cassette including a eukaryotic promoter, the coding sequence for the gene of interest, and a eukaryotic termination sequence. Following amplification, concatamers are subsequently processed according to their intended use and may include: restriction enzyme digestion for the production of short expression cassettes (SECs); ligation steps to circularize the SEC (CNAs); and/or supercoiling steps to produce sCNAs. The final product contains nearly non-detectable levels of bacterial endotoxin.
PCT/US2005/045028 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof WO2006063355A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002590933A CA2590933A1 (en) 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof
EP05853854A EP1819828A2 (en) 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof
US11/792,800 US20080305142A1 (en) 2004-12-11 2005-12-12 Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof
AU2005314431A AU2005314431B2 (en) 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof
BRPI0515777-3A BRPI0515777A (en) 2004-12-11 2005-12-12 biosynthesis free from high quality nucleic acid cells and uses thereof
JP2007545717A JP2008522628A (en) 2004-12-11 2005-12-12 Cell-free biosynthesis of high quality nucleic acids and their use
PCT/US2006/023439 WO2007018744A2 (en) 2005-08-03 2006-06-14 Cell-free biosynthesis of nucleic acid
IL183778A IL183778A0 (en) 2004-12-11 2007-06-07 Cell free biosynthesis of high-quality nucleic acid and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63541804P 2004-12-11 2004-12-11
US60/635,418 2004-12-11
US68071605P 2005-05-13 2005-05-13
US60/680,716 2005-05-13
US70534805P 2005-08-04 2005-08-04
US60/705,348 2005-08-04

Publications (2)

Publication Number Publication Date
WO2006063355A2 WO2006063355A2 (en) 2006-06-15
WO2006063355A3 true WO2006063355A3 (en) 2006-10-19

Family

ID=36337344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045028 WO2006063355A2 (en) 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof

Country Status (9)

Country Link
US (1) US20080305142A1 (en)
EP (1) EP1819828A2 (en)
JP (1) JP2008522628A (en)
KR (1) KR20070093992A (en)
AU (1) AU2005314431B2 (en)
BR (1) BRPI0515777A (en)
CA (1) CA2590933A1 (en)
IL (1) IL183778A0 (en)
WO (1) WO2006063355A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018744A2 (en) * 2005-08-03 2007-02-15 Cytogenix, Inc. Cell-free biosynthesis of nucleic acid
GB0614825D0 (en) * 2006-07-26 2006-09-06 Medical Res Council Method for amplification of ligation reactions
WO2009045344A2 (en) 2007-09-28 2009-04-09 Pacific Biosciences Of California, Inc. Error-free amplification of dna for clonal sequencing
FR2924440B1 (en) 2007-12-04 2015-01-09 Pf Medicament NEW METHOD FOR GENERATING AND SCREENING AN ANTIBODY BANK
US20100008939A1 (en) * 2008-07-09 2010-01-14 General Electric Company Unprocessed rolling circle amplification product
US9125845B2 (en) 2008-07-09 2015-09-08 General Electric Company DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
JP2013126953A (en) * 2010-03-31 2013-06-27 Terumo Corp Production method for liposome preparation
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
US11001868B2 (en) * 2017-08-11 2021-05-11 Global Life Sciences Solutions Operations UK Ltd Cell-free protein expression using double-stranded concatameric DNA
US10350307B2 (en) 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
AU2020351204A1 (en) 2019-09-18 2022-04-21 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
EP4083227A1 (en) * 2021-04-29 2022-11-02 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases
EP4310182A1 (en) * 2022-07-19 2024-01-24 4basebio UK Ltd Protected dna and methods for the production thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190608A1 (en) * 1999-11-12 2003-10-09 Gary Blackburn Microfluidic devices comprising biochannels
WO2005003389A2 (en) * 2003-06-28 2005-01-13 Royal Holloway And Bedford New College In vitro amplification of dna

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750338A (en) * 1986-10-23 1998-05-12 Amoco Corporation Target and background capture methods with amplification for affinity assays
US4994372A (en) * 1987-01-14 1991-02-19 President And Fellows Of Harvard College DNA sequencing
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5198543A (en) * 1989-03-24 1993-03-30 Consejo Superior Investigaciones Cientificas PHI29 DNA polymerase
US5001050A (en) * 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US6261808B1 (en) * 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US6410277B1 (en) * 1993-02-19 2002-06-25 Takara Shuzo Co., Ltd. DNA polymersases with enhanced length of primer extension
US5432065A (en) * 1993-03-30 1995-07-11 United States Biochemical Corporation Cycle sequencing with non-thermostable DNA polymerases
US5714320A (en) * 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
US6096880A (en) * 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
CA2135579A1 (en) * 1993-11-12 1995-05-13 Gerald James Mcnabb Solid fertilizer with a modifier bound to its surfaces
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
WO1995028175A1 (en) * 1994-04-19 1995-10-26 Thomas Jefferson University Viral ribonucleocapsid as an immunological enhancer
US6054299A (en) * 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5614365A (en) * 1994-10-17 1997-03-25 President & Fellow Of Harvard College DNA polymerase having modified nucleotide binding site for DNA sequencing
US5602011A (en) * 1995-01-18 1997-02-11 Pharmacia Biotech Inc. Purified Thermococcus barossii DNA polymerase
CA2222744C (en) * 1995-05-31 2008-03-25 Amersham Life Science, Inc. Thermostable dna polymerases
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DE69612013T2 (en) * 1995-11-21 2001-08-02 Univ Yale New Haven UNIMOLECULAR SEGMENT AMPLIFICATION AND DETERMINATION
ATE238434T1 (en) * 1995-12-05 2003-05-15 Jorn Erland Koch A CASCADED DUPLICATION REACTION OF NUCLEIC ACIDS
JP4073038B2 (en) * 1995-12-15 2008-04-09 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション Thermostable DNA polymerase from Thermoanaerobacter thermohydrosulfurica and its mutant enzyme from which exonuclease activity has been removed
US5827716A (en) * 1996-07-30 1998-10-27 Amersham Life Science, Inc. Modified Pol-II type DNA polymerases
US6011148A (en) * 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US5882904A (en) * 1997-08-04 1999-03-16 Amersham Pharmacia Biotech Inc. Thermococcus barossii DNA polymerase mutants
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US6787305B1 (en) * 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
EP1985714B1 (en) * 1998-03-25 2012-02-29 Olink AB Method and kit for detecting a target molecule employing at least two affinity probes and rolling circle replication of padlock probes
EP1086209B1 (en) * 1998-06-17 2007-08-22 Amersham Biosciences Corp. Fy7 polymerase
US6316229B1 (en) * 1998-07-20 2001-11-13 Yale University Single molecule analysis target-mediated ligation of bipartite primers
JP2002525078A (en) * 1998-09-15 2002-08-13 イェール ユニバーシティ Artificial long terminal repeat
US6235502B1 (en) * 1998-09-18 2001-05-22 Molecular Staging Inc. Methods for selectively isolating DNA using rolling circle amplification
EP2287338B1 (en) * 1998-11-09 2012-09-05 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US6830884B1 (en) * 1998-12-15 2004-12-14 Molecular Staging Inc. Method of amplification
JP2000225335A (en) * 1999-02-04 2000-08-15 Shimadzu Corp Apparatus for automatic synthesis
US6300069B1 (en) * 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
WO2001038546A1 (en) * 1999-11-23 2001-05-31 Amersham Biosciences Corp Improving dideoxynucleotide-triphosphate utilization by the hyper-thermophilic dna polymerase from the archaeon pyrococcus furiosus
US6221603B1 (en) * 2000-02-04 2001-04-24 Molecular Dynamics, Inc. Rolling circle amplification assay for nucleic acid analysis
WO2001066138A2 (en) * 2000-03-07 2001-09-13 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
US6291187B1 (en) * 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
WO2002066611A2 (en) * 2001-02-16 2002-08-29 The Board Of Trustees Of The Leland Stanford Junior University Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
US6617137B2 (en) * 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US7309575B2 (en) * 2002-01-16 2007-12-18 The University Of North Carolina At Chapel Hill Protein purification and detection methods
US20030180781A1 (en) * 2002-03-25 2003-09-25 The Regents Of The University Of California Constructing very long DNA sequences from synthetic DNA molecules
US6815167B2 (en) * 2002-04-25 2004-11-09 Geneohm Sciences Amplification of DNA to produce single-stranded product of defined sequence and length
EP1572943B1 (en) * 2002-08-29 2015-04-22 The Board of Trustees of The Leland S. Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
AU2004254552B2 (en) * 2003-01-29 2008-04-24 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
JP2006042601A (en) * 2003-04-25 2006-02-16 Yaeta Endo High throughput synthetic system
CA2521520A1 (en) * 2003-04-29 2004-11-11 Amersham Biosciences Corp Multiply-primed amplification of nucleic acid sequences
US20040223885A1 (en) * 2003-05-06 2004-11-11 Keen Randy E. Apparatus for the automated synthesis of polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190608A1 (en) * 1999-11-12 2003-10-09 Gary Blackburn Microfluidic devices comprising biochannels
WO2005003389A2 (en) * 2003-06-28 2005-01-13 Royal Holloway And Bedford New College In vitro amplification of dna

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAMPÀS ET AL: "DNA biochip arraying, detection and amplification strategies", TRENDS IN ANALYTICAL CHEMISTRY, vol. 23, January 2004 (2004-01-01), pages 49 - 62, XP004484688 *
DEAN ET AL: "Rapid amplification of plasmid and phage DNA using Phi29 DNA polymerase and multiply-primed rolling circle amplification", GENOME RESEARCH, vol. 11, 2001, pages 1095 - 1099, XP002261245 *
LUTHRA ET AL: "Isothermal multiple displacement amplification. A highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens", JOURNAL OF MOLECULAR DIAGNOSTICS, vol. 6, August 2004 (2004-08-01), pages 236 - 242, XP002371240 *
RECTOR ET AL: "A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification", JOURNAL OF VIROLOGY, vol. 78, May 2004 (2004-05-01), pages 4993 - 4998, XP002392144 *
WANG ET AL: "DNA amplification method tolerant to sample degradation", GENOME RESEARCH, vol. 14, November 2004 (2004-11-01), pages 2357 - 2366, XP002391762 *

Also Published As

Publication number Publication date
IL183778A0 (en) 2007-09-20
JP2008522628A (en) 2008-07-03
KR20070093992A (en) 2007-09-19
BRPI0515777A (en) 2008-08-05
US20080305142A1 (en) 2008-12-11
AU2005314431A1 (en) 2006-06-15
EP1819828A2 (en) 2007-08-22
CA2590933A1 (en) 2006-06-15
AU2005314431B2 (en) 2011-02-17
WO2006063355A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006063355A3 (en) Cell free biosynthesis of high-quality nucleic acid and uses thereof
WO2004024749A3 (en) Thermostable reverse transcriptases and uses thereof
KR20080028902A (en) Genetically modified yeast of the species issatchenkia orientalis and closely related species and fermentation processes using same
WO2003033519A3 (en) Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
WO2001007626A3 (en) Methods for producing l-amino acids by increasing cellular nadph
JPWO2016080424A1 (en) Method for amplifying circular DNA
CN108138193A (en) Lactics and the method using its production lactic acid
JP2023540797A (en) base editing enzyme
WO2003072798A3 (en) Method for generating amplified rna
JP2023519953A (en) Class 2 type II CRISPR system
CN102782130B (en) High-expression promoter derived from kluyveromyces marxianus
WO2003092362A3 (en) Seed specific usp promoters for expressing genes in plants
JP4575338B2 (en) Cloning and expression method of target gene by homologous recombination
WO2007014544A3 (en) Stereoselective synthesis of chiral diols
Duan et al. An efficient microbial-based method for production of high-purity Monascus azaphilones pigments
EP3412765B1 (en) Method for producing mutant filamentous fungi
EP4137582A1 (en) Rolling circle reverse transcription of circular rna
KR20220061480A (en) Manufacturing method of circular nucleic acid template for producing high molecular weight protein using hydrogelated nucleic acid
WO2022159742A1 (en) Novel engineered and chimeric nucleases
US20100203587A1 (en) Use of dna gyrase inhibitors for in vitro polypeptide synthesis reactions
JP5915824B2 (en) Preparation methods for in vitro protein biosynthesis
EP3904511A1 (en) Single-chain dna synthesis method
JP2006020632A6 (en) Regulation of in vitro protein biosynthesis
JP5129498B2 (en) Nucleic acid cloning method
EP4130254A1 (en) Eukaryotic cell lysates comprising exogenous enzymes and methods for preparing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007545717

Country of ref document: JP

Ref document number: 183778

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006930

Country of ref document: MX

Ref document number: 2005853854

Country of ref document: EP

Ref document number: 2005314431

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2590933

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005314431

Country of ref document: AU

Date of ref document: 20051212

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005314431

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077015676

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 3059/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580046723.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005853854

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11792800

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0515777

Country of ref document: BR